Night vision and AMD

Article

Problems with night vision correlate to an increase in the risk of symptoms of both the wet and dry forms of age-related macular degeneration (AMD), according to study results published in the November issue of Ophthalmology.

Problems with night vision correlate to an increase in the risk of symptoms of both the wet and dry forms of age-related macular degeneration (AMD), according to study results published in the November issue of Ophthalmology.

Gui-shuang Ying, PhD of the Center for Preventive Ophthalmology and Biostatics, Philadelphia, US and colleagues conducted the multicentre, randomized Complications of Age-Related Macular Degeneration Prevention Trial (CAPT), which assessed night vision in a cohort study. Participants (n=1052) had >10 drusen of >125 µm and visual acuity (VA) of >20/40 bilaterally. Subjects completed a 10-item Night Vision Questionnaire (NVQ-10), after which one eye received laser treatment and the opposite eye was monitored but not treated. VA was assessed at baseline, six months and annually thereafter, for a period of up to six years. Choroidal neovascularization (CNV) and geographic atrophy (GA) were also assessed.

The mean NVQ-10 score at baseline was 70 (range: 3–100). Patients with lower NVQ-10 scores - those with the worst night vision - were more likely to lose >3 lines of VA bilaterally during follow-up, to develop GA and to suffer CNV. Following adjustment for potential influencing factors, the difference in risk levels remained statistically significant.

The team concluded that, independently of other factors, poor night vision is associated with a greater risk of losing >3 lines of VA, development of GA and incidence of CNV.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.